Product Name :
CID-16020046
Description:
CID-16020046 is a selective GPR55 LPI receptor antagonist with IC50 of 015 M
CAS:
834903-43-4
Molecular Weight:
425.44
Formula:
C25H19N3O4
Chemical Name:
4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-d]pyrazol-5-yl]benzoic acid
Smiles :
CC1C=CC(=CC=1)C1=NNC2=C1C(C1=CC(O)=CC=C1)N(C1C=CC(=CC=1)C(O)=O)C2=O
InChiKey:
VGUQVYZXABOXCX-UHFFFAOYSA-N
InChi :
InChI=1S/C25H19N3O4/c1-14-5-7-15(8-6-14)21-20-22(27-26-21)24(30)28(18-11-9-16(10-12-18)25(31)32)23(20)17-3-2-4-19(29)13-17/h2-13,23,29H,1H3,(H,26,27)(H,31,32)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
CID-16020046 is a selective GPR55 LPI receptor antagonist with IC50 of 015 M|Product information|CAS Number: 834903-43-4|Molecular Weight: 425.44|Formula: C25H19N3O4|Synonym:|C390-0219|Chemical Name: 4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-d]pyrazol-5-yl]benzoic acid|Smiles: CC1C=CC(=CC=1)C1=NNC2=C1C(C1=CC(O)=CC=C1)N(C1C=CC(=CC=1)C(O)=O)C2=O|InChiKey: VGUQVYZXABOXCX-UHFFFAOYSA-N|InChi: InChI=1S/C25H19N3O4/c1-14-5-7-15(8-6-14)21-20-22(27-26-21)24(30)28(18-11-9-16(10-12-18)25(31)32)23(20)17-3-2-4-19(29)13-17/h2-13,23,29H,1H3,(H,26,27)(H,31,32)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO: 85 mg/mL(199.{{Roxithromycin} site|{Roxithromycin} Bacterial|{Roxithromycin} Protocol|{Roxithromycin} Purity|{Roxithromycin} custom synthesis|{Roxithromycin} Epigenetics} 79 mM).{{Polymyxin B} web|{Polymyxin B} Anti-infection|{Polymyxin B} Technical Information|{Polymyxin B} Purity|{Polymyxin B} custom synthesis|{Polymyxin B} Epigenetics} Water: Insoluble.PMID:23537004 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|In yeast cells expressing human GPR55, CID16020046 antagonized agonist-induced receptor activation. In human embryonic kidney (HEK293) cells stably expressing human GPR55, the compound behaved as an antagonist on LPI-mediated Ca2+ release and extracellular signal-regulated kinases activation, but not in HEK293 cells expressing cannabinoid receptor 1 or 2 (CB1 or CB2). CID16020046 concentration dependently inhibited lysophosphatidylinositol (LPI)-induced activation of nuclear factor of activated T-cells (NFAT), nuclear factor κ of activated B cells (NF-κB) and serum response element, translocation of NFAT and NF-κB, and GPR55 internalization[2].|In Vivo:|CID16020046 improves inflammation in models of intestinal inflammation and reduces proinflammatory cytokines. CID16020046 does not change the locomotor and anxiety behavior of healthy mice[1].|References:|Angela StanÄiÄ, et al. Neurogastroenterol Motil. 2015, 27(10): 1432-1445.Kargl J, et al. J Pharmacol Exp Ther. 2013, 346(1):54-66.Products are for research use only. Not for human use.|